Please login to the form below

Not currently logged in
Email:
Password:

AI drug discovery

This page shows the latest AI drug discovery news and features for those working in and with pharma, biotech and healthcare.

BMS links up with Exscientia for $1.2bn AI drug discovery deal

BMS links up with Exscientia for $1.2bn AI drug discovery deal

Bristol Myers Squibb (BMS) has announced a new collaboration agreement with Exscientia to use artificial intelligence (AI) to discovery drug candidates across a number of therapeutic areas. ... Exscientia will take responsibility for the AI-design and

Latest news

  • Policy and public health: ML and AI in healthcare Policy and public health: ML and AI in healthcare

    With these facts in hand, the motivation for machine learning (ML) and artificial intelligence (AI) to address the issues of drug discovery speed, cost and lead candidate identification holds tremendous promise. ... The cost and time involved with

  • Recursion raises $121m for AI-led drug discovery Recursion raises $121m for AI-led drug discovery

    Like many AI-based drug discovery companies, Recursion began uses its technology in drug repurposing by scanning existing molecules, but has expanded into discovery of novel compounds for rare diseases and ... Numerous other companies are pioneering

  • Medicines Discovery Catapult to collaborate with LifeArc on new biomarkers Medicines Discovery Catapult to collaborate with LifeArc on new biomarkers

    position as a leader in the creation of biomarker strategies, and the application of technology innovation in drug discovery.”. ... This new partnership will see AI made available to all drug discovery researchers on a more cost-effective 'pay as you go

  • Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity

    Exscientia will use its Centaur Chemist AI drug discovery platform in the collaboration. ... The collaboration will involve Excientia applying its ‘full-stack’ AI drug discovery capabilities to the entire R&D project, from gene to the drug candidate.

  • AI specialist Exscientia buys Kinetic Discovery AI specialist Exscientia buys Kinetic Discovery

    Exscientia, a specialist in applying artificial intelligence to drug discovery, says that Kinetic’s biophysics technology will allow it to seed its AI algorithms with data generated from fragment screening and ... Exscientia’s expansion is a further

More from news
Approximately 2 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • AI and accelerated computing ring in new era for healthcare AI and accelerated computing ring in new era for healthcare

    How AI can reduce drug discovery timelines. Today, we can produce more biomedical data in about three months than the entire 300-year history of healthcare. ... Application frameworks bridge this gap by providing researchers and clinicians the tools for

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    Novartis is investing in artificial intelligence, in alliance with Microsoft, to improve processes, drug design and manufacturing. ... Big data and healthcare. Switzerland is also home to all the major IT companies and both pharma and biotechs are

  • Has AI been the key to tackling the COVID-19 pandemic? Has AI been the key to tackling the COVID-19 pandemic?

    attributes of the drug, they can also uncover whether drugs previously used for other treatments could be an effective cure for this virus. ... UK-based BenevolentAI is just one such company that has used AI and machine learning to aid drug discovery.

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    Drug discovery. AI has the potential to significantly reduce the costs and time associated with drug discovery, across medical divisions and also specifically in handling the immediate COVID threat. ... achieve. Insilico Medicine was able to do this

  • A snapshot of… Exscientia A snapshot of… Exscientia

    As a full stack AI drug discovery company, we generate our own data before combining the analytical power of AI with the creativity and expertise of our world-class scientists. ... However, another key business challenge in the AI drug discovery field is

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?
...